Status:
COMPLETED
A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This single arm study will assess the safety and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to current non-biologic DMARDs....
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- moderate to severe rheumatoid arthritis;
- inadequate response to current non-biologic DMARDs
Exclusion
- rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis;
- previous treatment with other biologics.
Key Trial Info
Start Date :
November 30 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 26 2010
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00810277
Start Date
November 30 2008
End Date
May 26 2010
Last Update
August 3 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Kanta-Hämeen Keskussairaala ; Reumatologia
Hämeenlinna, Finland, 13530
2
Kiljavan Lääketutkimus Oy
Hyvinkää, Finland, 05800
3
Kanta-Hämeen keskussairaala; Riihimäen aluesairaala Reumapoliklinikka
Riihimäki, Finland, 11101